NRD
PHAT icon

Nebula Research & Development’s Phathom Pharmaceuticals PHAT Stock Holding History

Nebula Research & Development’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-37,937
Closed -$364K – 648
2025
Q2 		$364K Buy
37,937
+9,116
+32% +$50.4K 0.03% 732
2025
Q1 		$181K Buy
28,821
+7,858
+37% +$47.7K 0.02% 875
2024
Q4 		$170K Buy
+20,963
New +$260K 0.02% 826

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Nebula Research & Development's PHAT Position: Q3 2025 in Review

Nebula Research & Development sold out of Phathom Pharmaceuticals (PHAT) in Q3 2025, closing a stake of 37,937 shares — an estimated $364K sold.

Nebula Research & Development first reported a position in PHAT in Q4 2024 and held it in 3 quarters. The position peaked at $364K in Q2 2025. 133 funds tracked by Wall St. Rank hold PHAT as of Q3 2025.

  • Nebula Research & Development reported no remaining Phathom Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Nebula Research & Development sold 37,937 Phathom Pharmaceuticals shares in Q3 2025, an estimated $364K.
  • Nebula Research & Development first reported a position in Phathom Pharmaceuticals in Q4 2024 and held it in 3 quarters.
  • Nebula Research & Development's Phathom Pharmaceuticals position peaked at $364K in Q2 2025.
  • 133 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q3 2025.

Based on Nebula Research & Development's 13F filing for Q3 2025.